A novel chlorin-PEG-folate conjugate with higher water solubility, lower cytotoxicity, better tumor targeting and photodynamic activity.
Techniques to enhance tumor targeting and to improve the aqueous solubility of anticancer drugs and photosensitizers have recently been the focus of much research. In this study, a folate-PEG-conjugated chlorin was synthesized and characterized. Because of the use of PEG as a linker, the new chlorin displayed increased aqueous solubility, with a solubility of 40.1mg/mL in PBS, and showed lower aggregation and cytotoxicity than its precursor, chlorin. Meanwhile, the introduction of folic acid to the new chlorin resulted in increased selectivity for folate-receptor-positive tumor cells (HeLa and Hep-2 cells); the cellular uptake of the new chlorin by HeLa and Hep-2 cells was strikingly higher than that of the precursor chlorin, and the photocytotoxicities of the new chlorin to HeLa and Hep-2 cells were 2.5 and 3.5 times greater than that of folate-free conjugate chlorin. During photodynamic therapy mediated by the new chlorin, both type I and type II reactions occur simultaneously.